Argenta

Argenta operates as the sole global Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) exclusively dedicated to the animal health sector. The company provides comprehensive, end-to-end services that guide clients from the initial concept ('molecule') to the final commercial product ('market').

The business was established in Auckland, New Zealand, in 2006 by Dr. Doug Cleverly, a research chemist with extensive experience in animal health. Cleverly, after working for the US animal health giant Merial, identified a gap in the market for a specialized service provider that could offer high-quality research, development, and manufacturing services to animal health companies of all sizes. He co-founded the company, merging the research capabilities of his first startup, Chemlabs, with a contract manufacturing plant. This venture was born from his vision to apply New Zealand's problem-solving ingenuity on a global scale, starting with a small team and growing significantly. By 2019, Dr. Cleverly transitioned from his executive leadership role to a director and shareholder, continuing to support strategic customer engagement.

Argenta’s business model is centered on a collaborative partnership approach, serving as the outsourced R&D and manufacturing arm for its clients, which include the world's top animal health companies. The company does not market products under its own brand; instead, it develops and manufactures them for other firms to commercialize. Revenue is generated by providing a broad spectrum of services, including pharmaceutical sciences, formulation development, (pre)clinical research, regulatory services, and manufacturing of finished dosage forms like liquids, solids, and semi-solids. The company caters to both the livestock and companion animal markets.

The firm's 'Molecule to Market' service portfolio is extensive. It covers the entire product development lifecycle, from early-stage proof-of-concept and clinical development to regulatory affairs and large-scale manufacturing. Argenta specializes in areas like novel drug delivery technologies and the development of complex therapies. Over the years, Argenta has expanded its global footprint and capabilities through strategic acquisitions, including AlcheraBio in the US (2008), a manufacturing facility in Scotland (2017), and more recently, Klifovet, Pen & Tec Consulting, and Ondax Scientific in Europe. These acquisitions have been integrated under the unified Argenta brand to provide seamless global support, helping clients navigate regulatory submissions to agencies like the FDA and EMA. The company operates from FDA and EMA-approved sites in New Zealand, the United States, the United Kingdom, Spain, and Germany.

Keywords: animal health, CRO, CDMO, veterinary pharmaceuticals, contract research, contract manufacturing, molecule to market, drug development, regulatory affairs, clinical research, livestock health, companion animals, pharmaceutical sciences, drug delivery technologies, animal nutrition, veterinary medicine, formulation development, product commercialization, global animal health, preclinical testing